Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

Hisse Senetlerindeki Sıralama #2248
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Hisse Fiyatı
$138.50
Son senkronizasyon: 2026-10-20
Piyasa Değeri
$8.96B
Değişim (1 gün)
3.02%
Değişim (1 yıl)
84.67%
Ülke
US
Ticaret Protagonist Therapeutics, Inc. (PTGX)

Kategori

Healthcare
Protagonist Therapeutics, Inc. (PTGX) için hisse bölünme geçmişi
Protagonist Therapeutics, Inc. hissesi (sembol: PTGX) toplamda 0 hisse bölünmesi yaşamıştır.
En son hisse bölünmesi Oct 21, 2026 tarihinde gerçekleşmiştir.
Oct 21, 2026 tarihinden önce alınan bir PTGX hissesi bugün 0 PTGX hissesine eşdeğerdir.
Hisse bölünme listesi
Yıl Bölünme Çarpan Kümülatif Çarpan
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için hisse bölünmeleri
Şirket Hisse bölünme sayısı Kümülatif Çarpan Ülke
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL